| Dana Alkhandak, | |
|
802 Magnolia Ave Ste 208, Corona, CA 92879-3157 | |
| (951) 736-1630 | |
| Not Available |
| Full Name | Dana Alkhandak |
|---|---|
| Gender | Female |
| Speciality | Audiologist |
| Location | 802 Magnolia Ave Ste 208, Corona, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235903188 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 3856 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dana Alkhandak, 5555 Garden Grove Blvd Ste 200, Westminster, CA 92683-8234 Ph: (714) 804-5725 | Dana Alkhandak, 802 Magnolia Ave Ste 208, Corona, CA 92879-3157 Ph: (951) 736-1630 |
News Archive
Somaxon Pharmaceuticals, Inc. today announced that it has priced an underwritten public offering of 8,800,000 shares of its common stock at a price to the public of $2.95 per share. The offering is expected to close on or about November 24, 2010, subject to customary closing conditions.
In the U.S. and around the world, the popularity of minimally invasive cosmetic procedures continues to increase. Soft tissue injectables, also known as dermal fillers, are popular procedures that improve the appearance of aging and sun-damaged skin by restoring lost volume and filling lines.
When ovarian cancer spreads from the ovaries it almost always does so to a layer of fatty tissue that lines the gut.
Wyeth and its business partner, Nycomed, have announced the U.S. launch of Wyeth's own generic version of PROTONIX tablets, in response to the at-risk launch of generic pantoprazole tablets in the U.S. by Teva Pharmaceuticals USA, Inc. on December 21, 2007.
ChemoCentryx, Inc., today announced that it reported positive data with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 (Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial-1). Traficet-EN maintained a clinical remission rate (Crohn's Disease Activity Index (CDAI) less than 150) of approximately 50% in Crohn's patients over the course of 36 weeks, whereas in the placebo group remission decreased progressively from 50% to 31%.
› Verified 2 days ago
Dr. Donna Lynn Eskwitt, PH.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1867 California Ave Ste 101, Corona, CA 92881 Phone: 714-692-2270 | |
Connect Hearing, Inc. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 1101 California Ave Ste 100, Corona, CA 92881 Phone: 951-739-4689 Fax: 951-739-4690 | |
Mrs. Heather Jean Hopping, M.A.,CCC-A Audiologist Medicare: Not Enrolled in Medicare Practice Location: 802 Magnolia Ave Suite 208, Corona, CA 92879 Phone: 888-333-9152 Fax: 763-268-4280 |